PAP
BBIO icon

Persistent Asset Partners’s BridgeBio Pharma BBIO Stock Holding History

Persistent Asset Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-536
Closed -$72K – 347
2025
Q4 		$72K Buy
+536
New +$35.2K 0.03% 282

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Persistent Asset Partners's BBIO Position: Q2 2026 in Review

Persistent Asset Partners reduced its BridgeBio Pharma (BBIO) stake by 98% in Q2 2026, selling an estimated $1.63M and leaving 526 shares worth $39.2K. The position accounts for 0.01% of the portfolio, ranked #505.

Persistent Asset Partners first reported a position in BBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.77M in Q1 2026. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Persistent Asset Partners held 526 shares of BridgeBio Pharma worth $39.2K as of Q2 2026.
  • Persistent Asset Partners sold 23,284 BridgeBio Pharma shares in Q2 2026, an estimated $1.63M.
  • BridgeBio Pharma made up 0.01% of Persistent Asset Partners's portfolio in Q2 2026, its #505 holding.
  • Persistent Asset Partners first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 3 quarters since.
  • Persistent Asset Partners's BridgeBio Pharma position peaked at $1.77M in Q1 2026.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.